Histone Protein of interest for 21st Century
Many of the major human diseases, such as cancer, heart,
neurodegenerative and psychiatric disorder correlated with modifications in the
residues region of histone pos-translational modification. The residues in the
N-terminal region of histone are covalentely modified by acetylation,
methylation and phosphorylation. Histone is normally modified by acetylation
reaction catalyzed by histone enzyme acetyltransferase (HAT). This process can
make the structure of chromatin to open and facilitate transcription process.
Also, the reaction can be catalyzed in the opposite direction (is reversible)
by the histone enzyme deacetylase (HDAC) and it removed acetyl groups and then
changed the conformation of chromatin to close, and this could possible turn
genes off and thus making transcription unavailable. Some studies found that histone
deacetylase enzyme plays a major role in DNA methyltransferases in silencing
tumor suppressor genes. For instance, methylation of lysine 9 on histone H3 can
turn genes off by changing a chromatin configuration whereas methylation of
lysine 4 on histone H3 is turning genes on(Abel, 2008 and Filipe,2010).
The researchers saw histone methylation, DNA methylation as epigenetic
mechanisms that could block the expression of tumor suppressor genes. It can be
a potential therapeutic for cancer, neurodegenerative disorder and heart
disease.
Figure: Acetylation and deacetylation
of lysine residues.
http://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=3380189_12263_2012_283_Fig1_HTML.jpg
Referenceshttp://onlinelibrary.wiley.com/doi/10.1002/cncr.25482/full
Third Article
This
research paper has shown that histone deacetylase inhibitor as a possible way
to treat the human life threating diseases.
For instance, In October 2006 the FDA approved
vorinostat (HDACi drug) for the treatment of advanced forms of cutaneous T-cell lymphoma. But there are still some research requirements
to approve bioactivity in vitro and in vivo of HDACi.